Stockholm, Sweden, September 2, 2025 – AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing novel contractile agents to treat patients with heart failure, announces today the appointment of Philipp Mathieu as Chief Financial Officer (CFO).
Philipp is an experienced healthcare executive with two decades of leadership and investment experience across European and US markets. He has successfully led companies, driven healthcare investments, and advised on major strategic transactions across the sector. Most recently, he served as Chief Executive Officer of Immunovia AB, a publicly listed diagnostics company, and previously held senior roles in healthcare investment banking as well as advisory positions for international family offices and investors. He holds an MSc in Finance from Cass Business School, London, UK and an MSc in Economics from Georg-August University Göttingen, Germany.
Philipp Mathieu commented: “AnaCardio is one of the most exciting biotech scale-ups in the cardiovascular space and at the forefront of innovation in cardiovascular medicine, with the potential to transform the treatment of heart failure. With an exceptional team, a strong scientific foundation, and ambitious growth plans backed by leading investors, the company is uniquely positioned to make a significant impact. I am excited to join AnaCardio at this pivotal stage and to help accelerate its journey.”
“I am pleased to welcome Philipp to the AnaCardio management team. Philipp´s strong strategic mindset and extensive experience in healthcare transactions and financings will greatly strengthen our ability to advance our promising heart failure program.”, commented Patrik Strömberg, CEO.
About AnaCardio
AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. AnaCardio is based in Stockholm, Sweden.
Find more information about AnaCardio at www.anacardio.com and follow us on LinkedIn.
For further information, please contact:
Patrik Strömberg, CEO
Telephone: +46 704 156 159
E-mail: patrik.stromberg@anacardio.com
